Cargando…

Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells

Treatment of transformed breast duct epithelial cells with IL-6 produces a unique cellular phenotype characterized by diminished proliferation and increased motility. Human ductal carcinoma cells (T- 47D and ZR-75-1 lines) are typically epithelioid in shape and form compact colonies in culture. Time...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189517/
https://www.ncbi.nlm.nih.gov/pubmed/2553849
_version_ 1782146660717035520
collection PubMed
description Treatment of transformed breast duct epithelial cells with IL-6 produces a unique cellular phenotype characterized by diminished proliferation and increased motility. Human ductal carcinoma cells (T- 47D and ZR-75-1 lines) are typically epithelioid in shape and form compact colonies in culture. Time-lapse cinemicrography shows that some untreated cells can transiently become fusiform or stellate in shape and separate from each other within a colony, but they usually rejoin their neighbors. While IL-6 suppresses the proliferation of these carcinoma cells, the IL-6-treated cells generally become stellate or fusiform and show increased motility. These changes persist as long as the cells are exposed to IL-6. This results in the dispersal of cells within colonies. The effects on cell growth, shape, and motility are reversible upon removal of IL-6. IL-6-treated T-47D cells display diminished adherens-type cell junctions, as indicated by markedly decreased vinculin-containing adhesions and intercellular desmosomal attachments. The effects on ZR-75-1 cell shape, colony number, and DNA synthesis are dependent on IL-6 concentration in the range from 0.15 to 15 ng/ml. Higher concentrations are required in T-47D cells for equivalent effects. Anti-IL-6 immune serum blocks IL-6 action. IL-6 represents a well-characterized molecule that regulates both the proliferation and junction-forming ability of breast ductal carcinoma cells.
format Text
id pubmed-2189517
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21895172008-04-17 Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells J Exp Med Articles Treatment of transformed breast duct epithelial cells with IL-6 produces a unique cellular phenotype characterized by diminished proliferation and increased motility. Human ductal carcinoma cells (T- 47D and ZR-75-1 lines) are typically epithelioid in shape and form compact colonies in culture. Time-lapse cinemicrography shows that some untreated cells can transiently become fusiform or stellate in shape and separate from each other within a colony, but they usually rejoin their neighbors. While IL-6 suppresses the proliferation of these carcinoma cells, the IL-6-treated cells generally become stellate or fusiform and show increased motility. These changes persist as long as the cells are exposed to IL-6. This results in the dispersal of cells within colonies. The effects on cell growth, shape, and motility are reversible upon removal of IL-6. IL-6-treated T-47D cells display diminished adherens-type cell junctions, as indicated by markedly decreased vinculin-containing adhesions and intercellular desmosomal attachments. The effects on ZR-75-1 cell shape, colony number, and DNA synthesis are dependent on IL-6 concentration in the range from 0.15 to 15 ng/ml. Higher concentrations are required in T-47D cells for equivalent effects. Anti-IL-6 immune serum blocks IL-6 action. IL-6 represents a well-characterized molecule that regulates both the proliferation and junction-forming ability of breast ductal carcinoma cells. The Rockefeller University Press 1989-11-01 /pmc/articles/PMC2189517/ /pubmed/2553849 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells
title Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells
title_full Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells
title_fullStr Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells
title_full_unstemmed Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells
title_short Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells
title_sort interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189517/
https://www.ncbi.nlm.nih.gov/pubmed/2553849